Beta Drugs Ltd (BDL) has developed an In-house Azacitidine Oral which is a New Drug Delivery System (NDDS) formulation of Azacytidine Injection, with the brand name of MDS-O.
Changing lives of millions in ONCOLOGY
100 SKU's including Solid tumor, Hematology & Supportive.
99% products are Own Manufactured and In-house API.
49 Oncology companies are our clients.
25 upcoming products destined to make waves in oncology segment.
Beta drugs Ltd. gained the confidence of Oncologist across India & build a leadership position. We have a strong pipeline of new products. It will increase accessibility of more safe & effective Oncology drugs at affordable cost to Indian patients.Read More
Adsunib is the first branded generic of Sunitinib with all dosage strength of 12.5/25/50 mg tablets, used for the treatment of Renal Cell Carcinoma (RCC), Gastro-Intestinal tumor (GIST) & Pancreatic Neuroendocrine Tumor (pNET).
Gemcitabine is a chemotherapy medication used to treat a number of types of cancer. These cancers include breast cancer, ovarian cancer, non-small cell lung cancer, pancreatic cancer, and bladder cancer.
Beta Drugs Ltd today announced to receive WHO- GMP approval for its API plant (Adley Labs Ltd.). This accreditation will open the door for accelerated growth in the coming years. It will not only help to consolidate the company’s API business in the domestic market but also leverage benefits in export market.
ADLANTE (Lenavtinib) & ADLEAP (Enzalutamide) are being launched at very competitive prices than the existing available generic brands in India. Both the drugs are considered to be the mainstay treatment for Thyroid cancer and Prostate cancer globally.
Beta Drugs Ltd today announced to launch of Dasatinib with the name of Beedan. It is available in 3 SKUs: 20mg,50mg,70mg & 100mg